Program
ALN-6400
A development code.
Its studies are mostly in von Willebrand Diseases · Telangiectasia, Hereditary Hemorrhagic, led by Alnylam Pharmaceuticals.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Alnylam Pharmaceuticals | 22 open or running | phase 2since Oct 24, 2024 | Oct 24, 2024 | Jun 30, 2027phase 2 · NCT07575308 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Oct 24, 2024First study: phase 2 study in Telangiectasia, Hereditary HemorrhagicFirst studyNCT06659640 · 89 enrolled · United States, Australia, Canada and more
- May 4, 2026Phase 2 study in von Willebrand DiseasesNCT07575308 · 24 planned · United States, Germany, Netherlands and more
Ahead
- Jun 30, 2027Primary completion: phase 2 study in von Willebrand DiseasesNCT07575308
- Jan 5, 2028Primary completion: phase 2 study in Telangiectasia, Hereditary HemorrhagicNCT06659640
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 2 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07575308von Willebrand Diseases · United States, Germany, Netherlands and more | 2 | Recruiting | Jun 30, 2027 | 24 |
| NCT06659640Telangiectasia, Hereditary Hemorrhagic · United States, Australia, Canada and more | 2 | Active, not recruiting | Jan 5, 2028 | 89 |
How it is read
Names in the registry
- “ALN-6400”, 2 entries
Codes read as this program: ALN6400.
Conditions, from the studies’ own filings
- von Willebrand Diseases, 1 study
- Telangiectasia, Hereditary Hemorrhagic, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.